10x Genomics Preliminary Q3 Revenue Of ~$151.7M, Down 1% YoY
10x Genomics Preliminary Q3 Revenue Of ~$151.7M, Down 1% YoY
Preliminary Select Third Quarter 2024 Results
2024年第三季度初步選擇結果
- Revenue of approximately $151.7 million for the third quarter ended September 30, 2024, representing an approximate 1% decrease from the corresponding prior year period.
- Preliminary revenue by source for the third quarter is expected to be as follows:
- Instruments revenue of approximately $19.1 million, representing a 46% decrease from the corresponding prior year period. Instruments revenue consists of approximately $7.6 million of Chromium instruments revenue and $11.4 million of Spatial instruments revenue.
- Consumables revenue of approximately $126.2 million, representing 10% growth over the corresponding prior year period. Consumables revenue consists of approximately $96.5 million of Chromium consumables revenue and $29.7 million of Spatial consumables revenue.
- Services revenue of approximately $6.4 million, representing 48% growth over the corresponding prior year period.
- Preliminary revenue by geography for the third quarter is expected to be as follows:
- Americas revenue of approximately $87.8 million, an 11% decrease from the prior year period.
- EMEA revenue of approximately $37.9 million, an 18% increase over the prior year period.
- APAC revenue of approximately $26.0 million, a 15% increase over the prior year period.
- Cash and cash equivalents of approximately $398 million as of September 30, 2024.
- 2024年9月30日結束的第三季度營業收入約爲$15170萬，較去年同期大約下降1%。
- 預計第三季度按來源劃分的初步營業收入如下：
- 儀器收入約爲$1910萬，較去年同期下降46%。儀器收入包括大約$760萬的Chromium儀器收入和$1140萬的Spatial儀器收入。
- 耗材收入約爲$12620萬，較去年同期增長10%。耗材收入包括大約$9650萬的Chromium耗材收入和$2970萬的Spatial耗材收入。
- 服務收入約爲$640萬，較去年同期增長48%。
- 第三季度按地理位置劃分的初步營業收入預計如下：
- 美洲營業收入約爲$8780萬，較去年同期下降11%。
- 歐洲、中東、非洲營業收入約爲3790萬美元，比上年同期增長18%。
- 亞太地區營業收入約爲2600萬美元，比上年同期增長15%。
- 截至2024年9月30日，現金及現金等價物約爲39800萬美元。
"Third quarter revenue fell short of our expectations," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "The previously announced modifications we made to our commercial processes and organization to increase effectiveness represented a significant change in how we engage with customers. The transition was more disruptive than we anticipated, especially in the Americas. At the same time, our customers continue to be cautious with their spending, particularly around capital purchases, which notably impacted instrument sales during the quarter. Despite these near-term headwinds, we are confident in the opportunity ahead and believe the steps we are taking will enable us to reach more customers, execute consistently across the portfolio and drive the broad democratization of our technologies."
"第三季度營業收入未達到我們的預期，" 10x genomics的聯合創始人兼首席執行官Serge Saxonov表示。"我們之前宣佈的對商業流程和組織所做的修改旨在提高效率，這代表了我們與客戶互動方式上的重大變化。過渡比我們預期的更具破壞性，尤其是在美洲地區。與此同時，我們的客戶繼續在支出方面保持謹慎，特別是在資本購買方面，這明顯影響了本季度的儀器銷售。儘管面臨短期風險，我們對未來機會充滿信心，並相信我們正在採取的措施將使我們能夠觸達更多客戶，跨整個產品系列實施一致，並推動我們技術的廣泛普及。"
